

Product datasheet for **TR305507**

B7-2 (CD86) Human shRNA Plasmid Kit (Locus ID 942)

Product data:

Product Type:	shRNA Plasmids
Product Name:	B7-2 (CD86) Human shRNA Plasmid Kit (Locus ID 942)
Locus ID:	942
Synonyms:	B7-2; B7.2; B70; CD28LG2; LAB72
Vector:	pRS (TR20003)
E. coli Selection:	Ampicillin
Mammalian Cell Selection:	Puromycin
Format:	Retroviral plasmids
Components:	CD86 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 942). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.
RefSeq:	NM_001206924 , NM_001206925 , NM_006889 , NM_175862 , NM_176892 , NM_006889.1 , NM_006889.2 , NM_006889.3 , NM_006889.4 , NM_175862.1 , NM_175862.2 , NM_175862.3 , NM_175862.4 , NM_001206924.1 , NM_001206925.1 , NM_176892.1 , BC040261
UniProt ID:	P42081
Summary:	This gene encodes a type I membrane protein that is a member of the immunoglobulin superfamily. This protein is expressed by antigen-presenting cells, and it is the ligand for two proteins at the cell surface of T cells, CD28 antigen and cytotoxic T-lymphocyte-associated protein 4. Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell. Binding of this protein with cytotoxic T-lymphocyte-associated protein 4 negatively regulates T-cell activation and diminishes the immune response. Alternative splicing results in several transcript variants encoding different isoforms.[provided by RefSeq, May 2011]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).